Literature DB >> 27438460

Effects of Depression Alleviation on ART Adherence and HIV Clinic Attendance in Uganda, and the Mediating Roles of Self-Efficacy and Motivation.

Glenn J Wagner1, Bonnie Ghosh-Dastidar2, Eric Robinson2, Victoria K Ngo2, Peter Glick2, Barbara Mukasa3, Seggane Musisi4, Dickens Akena4.   

Abstract

With depression known to impede HIV care adherence and retention, we examined whether depression alleviation improves these disease management behaviors. A sample of 1028 depressed HIV clients in Uganda enrolled in a cluster randomized controlled trial of two depression care models, and were surveyed over 12 months. Serial regression analyses examined whether depression alleviation was associated with self-reported antiretroviral therapy (ART) adherence and clinic attendance at month 12, and whether these relationships were mediated by self-efficacy and motivation. Among those with major depression, depression alleviation was associated with better ART adherence and clinic attendance at month 12; these relationships were fully mediated by self-efficacy at month 12, while adherence motivation partially mediated the relationship between depression alleviation and ART adherence. When both mediators were entered simultaneously, only self-efficacy was a significant predictor and still fully mediated the relationship between depression alleviation and adherence. These findings suggest that depression alleviation benefits both ART adherence and clinic attendance, in large part through improved confidence and motivation to engage in these disease management behaviors.

Entities:  

Keywords:  Adherence; Clinic attendance; Depression; HIV; Motivation; Self-efficacy; Uganda

Mesh:

Substances:

Year:  2017        PMID: 27438460      PMCID: PMC5250618          DOI: 10.1007/s10461-016-1500-0

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  30 in total

1.  Mediation in experimental and nonexperimental studies: new procedures and recommendations.

Authors:  Patrick E Shrout; Niall Bolger
Journal:  Psychol Methods       Date:  2002-12

2.  Assessment of depression prevalence in rural Uganda using symptom and function criteria.

Authors:  Paul Bolton; Christopher M Wilk; Lincoln Ndogoni
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2004-06       Impact factor: 4.328

3.  Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trial.

Authors:  Alexander C Tsai; Dan H Karasic; Gwendolyn P Hammer; Edwin D Charlebois; Kathy Ragland; Andrew R Moss; James L Sorensen; James W Dilley; David R Bangsberg
Journal:  Am J Public Health       Date:  2012-06-21       Impact factor: 9.308

4.  Depressive symptoms increase risk of HIV disease progression and mortality among women in Tanzania.

Authors:  Gretchen Antelman; Sylvia Kaaya; Ruilan Wei; Jessie Mbwambo; Gernard I Msamanga; Wafaie W Fawzi; Mary C Smith Fawzi
Journal:  J Acquir Immune Defic Syndr       Date:  2007-04-01       Impact factor: 3.731

5.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

6.  Self-efficacy: toward a unifying theory of behavioral change.

Authors:  A Bandura
Journal:  Psychol Rev       Date:  1977-03       Impact factor: 8.934

7.  The effect of antidepressant treatment on HIV and depression outcomes: results from a randomized trial.

Authors:  Brian W Pence; Bradley N Gaynes; Julie L Adams; Nathan M Thielman; Amy D Heine; Michael J Mugavero; Teena McGuinness; James L Raper; James H Willig; Kristen G Shirey; Michelle Ogle; Elizabeth L Turner; E Byrd Quinlivan
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177

8.  Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.

Authors:  A John Rush; Maurizio Fava; Stephen R Wisniewski; Philip W Lavori; Madhukar H Trivedi; Harold A Sackeim; Michael E Thase; Andrew A Nierenberg; Frederic M Quitkin; T Michael Kashner; David J Kupfer; Jerrold F Rosenbaum; Jonathan Alpert; Jonathan W Stewart; Patrick J McGrath; Melanie M Biggs; Kathy Shores-Wilson; Barry D Lebowitz; Louise Ritz; George Niederehe
Journal:  Control Clin Trials       Date:  2004-02

9.  The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART.

Authors:  Viviane D Lima; Josie Geller; David R Bangsberg; Thomas L Patterson; Mark Daniel; Thomas Kerr; Julio S G Montaner; Robert S Hogg
Journal:  AIDS       Date:  2007-05-31       Impact factor: 4.177

10.  INtegration of DEPression Treatment into HIV Care in Uganda (INDEPTH-Uganda): study protocol for a randomized controlled trial.

Authors:  Glenn J Wagner; Victoria Ngo; Peter Glick; Ekwaro A Obuku; Seggane Musisi; Dickens Akena
Journal:  Trials       Date:  2014-06-25       Impact factor: 2.279

View more
  19 in total

1.  Female adherence self-efficacy before and after couple HIV testing and counseling within Malawi's Option B+ program.

Authors:  Austin Wesevich; Mina C Hosseinipour; Carol E Golin; Nuala McGrath; Mercy Tsidya; Limbikani Chimndozi; Nivedita Bhushan; Irving Hoffman; William C Miller; Nora E Rosenberg
Journal:  AIDS Care       Date:  2019-06-25

2.  Depressive Symptoms, Disclosure, HIV-Related Stigma, and Coping Following HIV Testing Among Outpatients in Uganda: A Daily Process Analysis.

Authors:  Susan M Kiene; Meredith Dove; Rhoda K Wanyenze
Journal:  AIDS Behav       Date:  2018-05

3.  Drug Use Mediates the Relationship Between Depressive Symptoms and Adherence to ART Among Recently Incarcerated People Living with HIV.

Authors:  Lauren M Hill; Carol E Golin; Nisha C Gottfredson; Brian W Pence; Bethany DiPrete; Jessica Carda-Auten; Jennifer S Groves; Sonia Napravnik; David Wohl; Kevin Knight; Patrick M Flynn
Journal:  AIDS Behav       Date:  2019-08

4.  Patient Engagement With an Automated Telephone Symptom Management Intervention: Predictors and Outcomes.

Authors:  Alla Sikorskii; Charles W Given; Barbara A Given; Asish Banik; John C Krauss
Journal:  Ann Behav Med       Date:  2020-06-12

5.  Changes in ART Adherence Relate to Changes in depression as Well! Evidence for the Bi-directional Longitudinal Relationship Between Depression and ART Adherence from a Prospective Study of HIV Clients in Uganda.

Authors:  Glenn J Wagner; Bonnie Ghosh-Dastidar; Barbara Mukasa; Sebastian Linnemayr
Journal:  AIDS Behav       Date:  2020-06

Review 6.  Depression and HIV: integrated care towards 90-90-90.

Authors:  Dixon Chibanda
Journal:  Int Health       Date:  2017-03-01       Impact factor: 2.473

7.  "It's because I think too much": Perspectives and experiences of adults with hypertension engaged in HIV care in northern Tanzania.

Authors:  Preeti Manavalan; Linda Minja; Lisa Wanda; Julian T Hertz; Nathan M Thielman; Nwora Lance Okeke; Blandina T Mmbaga; Melissa H Watt
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

8.  Depressive Symptoms, Gender, Disclosure, and HIV Care Stage Among People Living with HIV in Cameroon.

Authors:  Angela M Parcesepe; Molly Remch; Anastase Dzudie; Rogers Ajeh; Denis Nash; Kathryn Anastos; Marcel Yotebieng; Adebola Adedimeji; Eric Pefura-Yone; Kathryn Lancaster
Journal:  AIDS Behav       Date:  2021-08-17

9.  Effects of Depression Alleviation on Work Productivity and Income Among HIV Patients in Uganda.

Authors:  Glenn J Wagner; Bonnie Ghosh-Dastidar; Eric Robinson; Victoria K Ngo; Peter Glick; Seggane Musisi; Dickens Akena
Journal:  Int J Behav Med       Date:  2017-08

10.  Maternal depression treatment in HIV (M-DEPTH): Study protocol for a cluster randomized controlled trial.

Authors:  Glenn J Wagner; Ryan K McBain; Dickens Akena; Victoria Ngo; Janet Nakigudde; Juliet Nakku; Harriet Chemusto; Jolly Beyeza-Kashesya; Violet Gwokyalya; Laura J Faherty; Leticia Kyohangirwe; Linda Kisaakye Nabitaka; Hafsa Lukwata; Sebastian Linnemayr; Bonnie Ghosh-Dastidar; Juliet Businge; Barbara Mukasa; Rhoda K Wanyenze
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.